Springer Health+ IME: Podcast to Practice

International experts Andreea Nissenkorn, Antonio Gil-Nagel Rein and Takamichi Yamamoto discuss regional barriers to comprehensive, long-term care for Lennox-Gastaut syndrome, identifying system-level, cultural, and resource-based factors influencing treatment access and care coordination.

International experts Andreea Nissenkorn, Antonio Gil-Nagel Rein and Takamichi Yamamoto explore regional treatment differences for Lennox-Gastaut syndrome, including therapy availability, mechanisms of action, and selection rationale, in order to optimize individualized care strategies.

International experts Andreea Nissenkorn, Antonio Gil-Nagel Rein and Takamichi Yamamoto examine regional differences in Lennox-Gastaut syndrome diagnosis and treatment guidelines, identifying barriers and opportunities to align care across healthcare systems.

International experts Andreea Nissenkorn, Antonio Gil-Nagel Rein and Takamichi Yamamoto examine the burden of disease, offering a holistic view of the real-world burden of Lennox-Gastaut syndrome on patients and caregivers.

International experts Andreea Nissenkorn, Antonio Gil-Nagel Rein and Takamichi Yamamoto examine the burden of disease, offering a holistic view of the real-world burden of Lennox-Gastaut syndrome on patients and caregivers.

International experts Andreea Nissenkorn, Antonio Gil-Nagel Rein and Takamichi Yamamoto elucidate the neurophysiological and genetic factors underpinning Lennox-Gastaut syndrome, highlighting key pathophysiological processes.

"Led by Prof. Martin Aringer and Dr. Wiebke Troll A one-to-one conversation between an expert and a patient advocate, focusing on lived experience, treatment adherence, and shared decision-making.

Led by Prof. Martin Aringer, Prof. Marta Mosca and Dr. Johanna Mucke A discussion on regional disparities, barriers to guideline adoption, and practical solutions.

Led by Prof. Martin Aringer and Dr. Johanna Mucke Learn about validated tools like LLDAS and DORIS, and how to integrate them into routine care.

Led by Prof. Martin Aringer and Prof. Marta Mosca Explore the updated EULAR 2023 guidelines and how to implement treat-to-target strategies in clinical practice.

Dr. David Kerr discusses breakthrough data from ADA 2025 and the clinical implications for diabetic ketoacidosis management and ketone monitoring technology integration.

Dr. Kelly Gwathmey and Jude Kings discuss the importance of multidisciplinary teamwork in improving outcomes for patients with gMG.

Dr. Kelly Gwathmey and Dr. Sithara Ramdas discuss the evolving treatment landscape in gMG, including pediatric-specific considerations.

Dr. Kelly Gwathmey and Dr. Pushpa Narayanaswami discuss emerging B- and T-cell targeted therapies for gMG, highlighting recent clinical trials, mechanisms of action, and the evolving treatment paradigm.

Dr. Kelly Gwathmey and Dr. Pushpa Narayanaswami discuss clinical evidence and practical considerations for integrating FcRn antagonists and complement inhibitors into the treatment of gMG.

Prof. Amer Zeidan and Prof. Courtney D. DiNardo discuss the mechanism of action, efficacy, and safety profiles of novel targeted therapies for IDH1-mutant R/R AML.

Dr. Kelly Gwathmey and Dr. Sithara Ramdas discuss the clinical presentation, diagnostic challenges, and treatment considerations for both adult and juvenile myasthenia gravis.

Janel Worcester-Brown and Dr. Kelly Gwathmey engage in a compelling patient-physician discussion of the realities of living with gMG and the challenges patients face navigating their healthcare journey.

Prof. Amer Zeidan and Dr. Eunice Wang discuss the latest evidence-based regimens and guideline updates for the clinical application of targeted therapy in R/R AML.

Prof. Amer Zeidan and Dr. Sanam Loghavi discuss effective strategies for implementing molecular testing and overcoming barriers in clinical practice for R/R AML​.

Dr. Jennifer Green shares exciting CGM device highlights from the 2025 Standards of Care in Diabetes revision by the ADA.

Watch Professor Tina Vilsbøll and patient, Molly Boll, discuss the importance and benefits of effective patient communication, and challenges of SDM in T2D and CKD management.

Episode 9: Claire Paquet discusses the implications of the real-world and recommendation data presented on anti-amyloid antibody therapies for AD

Episode 8: Juan Fortea comments on future opportunities for anti-amyloid antibody treament given the consolidation of clinical trial data in the real world

Dr. Jennifer Green discusses breaking news and clinical implications of data presented at EASD 2024 on CGM technology use in type 2 diabetes.